(Boursier.com) — New cold shower for the shareholders of Carmat. The group, which had announced at the beginning of December, the voluntary suspension, on a temporary basis, of the implantations of its artificial heart Aeson due to a quality problem having affected some of its prostheses, will not finally resume its implantations in commercial and clinical settings. before next October. What cause a new violent drop in the title, which plunged 15.17% on Tuesday to end at 14.20 euros.
“A rigorous investigation led to the conclusion that quality defects on two distinct components of the prosthesis were at the origin of these problems. Corrective actions aimed at avoiding such defects have been defined, and are being integrated into production processes,” the group said.
At the same time, the company continues to exchange with the notified body (DEKRA) and the competent authorities (ANSM in France and the Food & Drug Administration in the United States), whose authorization is necessary to be able to resume the implantations. in the commercial context on the one hand, and in the context of clinical studies on the other hand.
The management has undertaken to communicate regularly with the market on the progress of the recovery process but also with the regulatory authorities, notes Oddo BHF. A first point will be made at least during the GA (05/11/2022). Unfortunately, pressure could continue on the title between now and its refinancing (upstream of the resumption of settlements), adds the broker. The company’s current valuation nevertheless leads it to maintain its ‘outperformance’ opinion with a target reduced from 42 to 35 euros.
©2022 Boursier.com